Conference Coverage

CMSC: Survey offers snapshot of MS therapy trends


 

AT THE CMSC ANNUAL MEETING

References

Difficulty can arise when the patient and the physician both agree on a DMT switch, but the patient’s health insurer says no. “The clinician’s best judgment is, ‘I’ve seen the MRI. There’s activity in the brain. I want to change to a different medication.’ But the insurance company says, ‘You don’t meet our criteria,’ ” said Gary R. Cutter, Ph.D., director of the NARCOMS Coordinating Center. “The patient doesn’t know what to do. The physician can fight [that decision by the insurer], can get involved in that battle. But that’s a different battle that not all physicians have the resources around to tackle. It can be a hassle for both the patient and physician.”

Dr. Gary Cutter

Dr. Gary Cutter

Dr. Cutter noted that MS patients who switch DMTs tend to do worse from a clinical standpoint. “If you look cross-sectionally at data, people who have switched end up with higher levels of disability, and it’s because the physician is reacting to something; it’s not that the drug they switched to is bad,” he said. “These drugs are not cures. They’re meant to slow the progression [of MS].”

NARCOMS is supported by the CMSC and the Foundation of the CMSC. Genentech provided additional support for the survey of treatment decision making. Dr. Cutter disclosed ties to several pharmaceutical companies. The other researchers stated that they had no financial conflicts to disclose.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

New patient registry aims to become ‘Framingham’ of MS
MDedge Internal Medicine
DMT may reduce disability-worsening events in multiple sclerosis
MDedge Internal Medicine
Interferon beta, glatiramer acetate prove effective for relapsing MS
MDedge Internal Medicine
FDA approves first generic version of MS drug glatiramer acetate
MDedge Internal Medicine
DECIDE: Daclizumab cuts MS relapse rate by 45%
MDedge Internal Medicine
Peginterferon beta-1a MS data show positive early and long-term results
MDedge Internal Medicine
AAN: Study supports safety of fingolimod for MS
MDedge Internal Medicine
Botox treatments improve urinary incontinence in neurogenic bladder dysfunction
MDedge Internal Medicine
VIDEO: Cannabis further compromises cognitive function in some MS patients
MDedge Internal Medicine
CMSC: Many menopausal and MS symptoms overlap
MDedge Internal Medicine